Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply

JAMA Oncology · Published 2026-06-04 · DOI 10.1001/jamaoncol.2026.1589

Authors (3)

Zoe Quandt, Megan Othus, Elad Sharon

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Quandt, Z., Othus, M., Sharon, E. (2026). Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2026.1589

Related articles

• Considerations in Genomic Therapy Matching—Reply · JAMA Oncology · 2026 · Same journal
• Survival Language · JAMA Oncology · 2026 · Same journal
• A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0 · JAMA Oncology · 2026 · Same journal
• Global Consensus on the Management of Primary Localized Chordoma · JAMA Oncology · 2026 · Same journal
• Survival in the SONIA Trial—Reply · JAMA Oncology · 2026 · Same journal
• When TNM Staging Is Not Sufficient · JAMA Oncology · 2026 · Same journal
• Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma · JAMA Oncology · 2026 · Same journal
• Treatment Delays in Early Age–Onset Colorectal Cancer · JAMA Oncology · 2026 · Same journal
• Interpretation of the BRIGHT-2 Trial · JAMA Oncology · 2026 · Same journal
• Error in Open Access License · JAMA Oncology · 2026 · Same journal